home / stock / lixt / lixt news

LIXT News and Press, Lixte Biotechnology Holdings Inc. From 03/21/24

Stock Information
Company Name: Lixte Biotechnology Holdings Inc.
Stock Symbol: LIXT
Market: OTC
Website: lixte.com
Menu
LIXT LIXT Quote LIXT Short LIXT News LIXT Articles LIXT Message Board
Get LIXT Alerts

News, Short Squeeze, Breakout and More Instantly...
LIXT - LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage ...
LIXT - Expected earnings - Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc. (LIXT) is expected to report for quarter end 2023-12-31

LIXT - Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

Conference In Dublin, Ireland on February 27 - 29, 2024 Focuses on How to Bring Basic Science Discoveries to the Clinic PASADENA, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW) (“LIXTE” or the ...

LIXT - LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced th...
LIXT - First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-1...

LIXT - LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunothe...

LIXT - IFRX, LIXT and IOAC are among pre market gainers

2023-11-03 08:18:52 ET Werewolf Therapeutics  ( HOWL ) +38% jumps on early-sage data from lead program. DigitalOcean Holdings  ( DOCN ) +23% stock jumps 20%, guides Q4 and FY figures above consensus. InflaRx ( IFRX ) +16% . Block ( SQ ) +1...
LIXT - LIXT, LIPO and HRYU among mid-day movers

2023-10-26 12:53:31 ET Gainers: MSP Recovery ( LIFW ) +31% . Blueprint Medicines Corp ( BPMC ) +27% . Global Mofy Metaverse Ltd ( GMM ) +23% . Endeavor Group Holdings ( EDR ) +23% . Impinj ( PI ) +22% . Bel Fuse ( BELFB )...

LIXT - LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

Extension Agreement Follows Successful Two-Year Collaboration in Colon Cancer PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration wit...

LIXT - LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the ...
Previous 10 Next 10